John Hood and his team sold Impact Biomedicines, Inc. – the company he co-founded in 2017 to develop the JAK2 inhibitor Inrebic (fedratinib) for myelofibrosis – to Celgene Corporation for $1.1bn up front in early 2018 and then the former Impact CEO took a few weeks off before seeking out his next project. Now, more than two years later, Hood has officially launched his latest start-up, known as Endeavor BioMedicines.
Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
Co-Founded By Former Impact Biomedicines CEO, Initial Focus Is IPF
John Hood spent the past few years looking for a drug candidate worth forming a new company around before he zeroed in on Lilly’s taladegib as a treatment for idiopathic pulmonary fibrosis.
More from Financing
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
More from Business
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.